Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05073315 · ClinicalTrials.gov registry record · Phase 3
A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 425
- Enrollment target
NCT05073315: Completed Phase 3 study, sponsored by Amgen.
NCT05073315 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 425 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05073315, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 425 participants
- Enrollment target
Study Summary
Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to severe plaque psoriasis. This multi-center study is composed of two periods: A lead-in period of treatment with Humira® followed by a randomized two parallel arm period.
Primary Outcome
Participants analyzed according to actual treatment received.
Interventions
- DRUG Adalimumab
- DRUG ABP 501
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 425 participants |
| Start Date | 2021-10-04 |
| Est. Completion | 2022-12-19 |
| Phase | Phase 3 |
What the finished NCT05073315 record still lists
NCT05073315 is an interventional study that assigns participants to a tested intervention. The registered 425 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (45% lower).
The record links to 0 conditions, and to 2 interventions - of which Adalimumab is the first listed.
NCT05073315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05073315 about?
NCT05073315 is a clinical study titled "A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque Psoriasis". Study to evaluate pharmacokinetics, efficacy, safety and immunogenicity of multiple switches between Humira® and ABP 501 (new high concentration formulation) compared with continued use of Humira® in participants with moderate to severe plaque psoriasis. This multi-center study is composed of two pe...
What is the current status of trial NCT05073315?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 425 participants. The study started on 2021-10-04. Estimated completion is 2022-12-19.
What interventions are being tested in trial NCT05073315?
The interventions under investigation include: Adalimumab (DRUG), ABP 501 (DRUG).
Who is sponsoring clinical trial NCT05073315?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05073315's enrollment target sits among peer trials
425 883rd of 2000 higher than 1,117 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04265430 · 425 participants · Phase 4
Serial Magnetic Resonance Imaging for the Prediction of Radiation-Induced Changes in Normal Tissue of Patients With Oral Cavity or Skull Base Tumors
- NCT04278690 · 425 participants · NA
Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit
- NCT05321368 · 425 participants · NA
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
- NCT05340738 · 425 participants · NA
AI-Based Fidelity Feedback to Enhance CBT
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI